Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)
• By PharmAsia News
Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura
and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.